Get the Stockscreener App
9.27
1.49%
-0.14
After Hours:
9.25
-0.02
-0.22%
Oculis Holding Ag stock is traded at $9.27, with a volume of 239.58K.
It is down -1.49% in the last 24 hours and down -28.47% over the past month.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
See More
Previous Close:
$9.41
Open:
$9.71
24h Volume:
239.58K
Relative Volume:
0.86
Market Cap:
$514.74M
Revenue:
-
Net Income/Loss:
$-117.99M
P/E Ratio:
-4.3324
EPS:
-2.1397
Net Cash Flow:
$-79.92M
1W Performance:
-8.58%
1M Performance:
-28.47%
6M Performance:
-62.92%
1Y Performance:
-47.03%
1-Day Range:
$9.10
$9.71
1-Week Range:
$9.10
$10.84
52-Week Range:
$9.10
$34.48
Oculis Holding Ag Stock (OCS) Company Profile
Compare OCS vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
9.27 | 514.74M | 0 | -117.99M | -79.92M | -2.1397 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Initiated | JP Morgan | Overweight |
| Aug-27-25 | Initiated | Needham | Buy |
| Dec-05-23 | Initiated | Chardan Capital Markets | Buy |
| Oct-05-23 | Initiated | Stifel | Buy |
| Jun-14-23 | Initiated | BofA Securities | Buy |
| Jun-12-23 | Initiated | H.C. Wainwright | Buy |
| Jun-08-23 | Initiated | Robert W. Baird | Outperform |
| May-10-23 | Initiated | Pareto | Buy |
| Apr-28-23 | Initiated | Wedbush | Outperform |
View All
Oculis Holding Ag Stock (OCS) Latest News
(OCS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Oculis Holding AG (OCS) stock price, news, quote and history - Yahoo Finance UK
Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength? - Zacks Investment Research
H.C. Wainwright raises Oculis stock price target to $39 on DED trial progress - Investing.com Nigeria
Oculis Holding AG (OCS) Stock Analysis: Unveiling a Potential 254.75% Upside in the Biotech Space - DirectorsTalk Interviews
Oculis Holding AG: Navigating Through Major Trial Setback (NASDAQ:OCS) - Seeking Alpha
A board member bought Oculis shares - Stock Titan
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - marketscreener.com
Why (OCS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Oculis at H.C. Wainwright conference: biomarker bet and neurology push - Investing.com
OCS: Precision medicine and targeted trials drive clinical and commercial strategy, with strong funding - TradingView
Oculis at H.C. Wainwright conference: biomarker bet and neurology push By Investing.com - Investing.com Canada
Oculis Holding AG Ordinary shares (NASDAQ: OCS) Share Price, OCS Stock News, OCS Share Price & Updates - Kalkine
Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade - qz.com
Precision Trading with Oculis Holding Ag (OCS) Risk Zones - Stock Traders Daily
Oculis doses first patient in phase 3 privosegtor trial for ON - Glance by Eyes On Eyecare
Oculis Holding AG Warrants (OCSAW) Hold Steady at $4.79 as Consolidation ContinuesVolatility Smile - dars.gov.et
Oculis Holding - The Pharma Letter
H.C. Wainwright reiterates Oculis stock rating on trial start - Investing.com
There Is No Approved Specific Treatment for Acute Optic Neuritis. Oculis Is Testing One. - stocktitan.net
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis - manilatimes.net
Enterprise value to revenue forward of Oculis Holding AG – FWB:CR5 - TradingView
Oculis (OCS) Earnings Reading: EPS Lands Above Forecast in the Latest Session; Post-Report: The Share Price Adds 2.88% at the CloseReturn On Capital - dars.gov.et
Oculis (OCS) Daily Review: Rises 0.38% to $13.19 at the Close; Chart Reference: $12.53 and $13.85 Define the Nearby Reference Levels for the Current SessionAnchored VWAP - vinanet.vn
Oculis (OCSAW) Session-Level Review: Ends Up by 6.00% at $5.04 in the Latest Session; Current Setup: the Near-Term Reference Band Stretches From $4.79 to $5.29 in the Current UpdateAggressive Growth Picks - vinanet.vn
Oculis Holding (OCS) Advances 0.94% as Shares Hold Above Key SupportDouble Top - vinanet.vn
Stifel reiterates Buy rating on Oculis stock, $40 target By Investing.com - Investing.com Nigeria
The Technical Signals Behind (OCS) That Institutions Follow - Stock Traders Daily
Four Oculis directors' restricted stock units vest in Aug. 13 notifications - Stock Titan
Oculis (NASDAQ:OCS) Price Target Cut to $20.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect? - Zacks Investment Research
Stifel reiterates Buy rating on Oculis stock, $40 target - Investing.com
Oculis Holding AG Warrants (OCSAW) Hold Steady at $4.50 as Consolidation Range NarrowsVolatility Breakout Picks - Vinanet
Oculis buys out privosegtor’s global rights from Accure - Glance by Eyes On Eyecare
HC Wainwright Has Negative Estimate for Oculis Q3 Earnings - MarketBeat
Oculis rebuilds pipeline with Privosegtor buy from Accure - AllSci
Oculis Holding AG (OCS) Stock Price, News, Quote & History - Yahoo! Finance Canada
Oculis Announces Asset Purchase Agreement With Accure Therapeutics, Posts Q2 2026 Financial Results - VisionMonday.com
Oculis Holding (OCS) inks $3.8M cash-plus-shares deal for Privosegtor rights - Stock Titan
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company - The Manila Times
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, ... - pmg-ky3.com
Oculis to buy Accure rights to Privosegtor for $3.8 million plus up to 2,050,000 shares - Bitget
Oculis acquires full rights to Privosegtor, boo... - Pluang
Oculis to Acquire Full Global Rights to Privosegtor from Accure Therapeutics in Strategic Asset Purchase - Quiver Quantitative
Oculis Signs Asset Purchase Agreement with Accure - GlobeNewswire
Oculis Holding AG Warrants (OCSAW) Hold Steady at $4.50 as Consolidation ContinuesStandard Deviation - siam.in
Oculis Holding AG (OCS) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Oculis (NASDAQ:OCS) Announces Quarterly Earnings Results - MarketBeat
Oculis Holding earnings beat by CHF0.23, revenue topped estimates - Investing.com Nigeria
Wall Street Zen Upgrades Oculis (NASDAQ:OCS) to Sell - MarketBeat
Oculis Holding Ag Stock (OCS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):